by Admin Neo Lumina | Dec 1, 2023 | News
Canada recommends launch of Veterans psychedelic research programme A new report has been released by Canada’s Senate Subcommittee on Veterans Affairs – ‘The Time Is Now: Granting Equitable Access to Psychedelic Assisted Therapies’ – which recommends the launch of a...
by Admin Neo Lumina | Dec 1, 2023 | News
Psilocybin analogue shows positive results in Phase 2 depression study Cybin has announced positive Phase 2 topline safety and efficacy data for its proprietary deuterated psilocybin analogue – CYB003 – for the treatment of major depressive disorder (MDD). Results...
by Admin Neo Lumina | Dec 1, 2023 | News
Short Wave Pharma: innovating eating disorder care with psychedelics Psychedelic Health speaks to Short Wave Pharma CEO Rivki Stern about the company’s plans to innovate eating disorder care through psychedelics and its recent acquisition by Psych Capital. Short Wave...
by Admin Neo Lumina | Dec 1, 2023 | News
Compass Pathways launches Phase 3 psilocybin trial in UK Compass Pathways has confirmed that the UK component of its Phase 3 trial investigating psilocybin for treatment-resistant depression has now launched. The trial will be carried out at multiple sites in the UK,...
by Admin Neo Lumina | Nov 15, 2023 | News
Understanding variability in psychedelic treatment responses The US National Institute on Drug Abuse (NIDA) has earmarked $2 million in funding for psychedelic treatment research into Substance Use Disorder (SUD). NIDA will commit the funds to three to five awards...
by Admin Neo Lumina | Nov 7, 2023 | News
Filament Health targets substance use disorders with natural psychedelics Filament Health Corp (OTCQB:FLHLF)’s diversified business model makes it one of the only psychedelics companies to be already generating revenue. The Vancouver, British Columbia-based...
